isaralgagene civaparvovec vs Migalastat
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Fabry Disease
Shared mechanism: Alpha-galactosidase A (GLA / α-Gal A) · full Fabry Disease pipeline
isaralgagene civaparvovec
Developed by PTC Therapeutics and partners
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
Migalastat · Galafold
Marketed by Amicus Therapeutics and partners
NCT00925301 · Phase 3 · completed
Participants were randomized and double-blinded to migalastat or placebo, with 34 and 33 participants assigned respectively. The primary endpoint was a kidney biopsy measure of GL-3 inclusions, a surrogate pathology measure rather than a direct clinical outcome; 13 of 32 migalastat-treated participants versus 9 of 32 placebo-treated participants achieved the target reduction, but the comparison was not statistically significant (p=0.2996).
Next expected readout: December 2026 · NCT04020055 (registry estimate)
Reported efficacy
Percentage Of Participants With At Least A 50% Reduction From Baseline To Month 6 In The Average Number Of Kidney Interstitial Capillary (IC) Globotriaosylceramide (GL-3) Inclusions (Baseline, Month 6): Percentage Of Participants With At Least A 50% Reduction From Baseline To Month 6 In The Average Number Of Kidney Interstitial Capillary (IC) Globotriaosylceramide (GL-3) Inclusions (Baseline, Month 6): Migalastat — Responder: 13 Participants; Non-Responder: 19 Participants | Placebo — Responder: 9 Participants; Non-Responder: 23 Participants (missed)
Result source: NCT00925301
Results for Fabry Disease
There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.
isaralgagene civaparvovec: registry results are on file for Fabry Disease, but their comparison mappings are not yet available.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: isaralgagene civaparvovec's landscape · Migalastat's landscape